The annual meeting of the American Society of Clinical Oncology is almost upon us.
This oncology conference comes just once a year and is a hallmark event for the healthcare investing crowd. ASCO begins on May 29 and runs through June 2 in Chicago, Illinois. Abstracts will be made pubic two weeks in advance, on May 13, and abstract titles are released on Monday, April20.
As a precursor, we’ve put together a list of small- and mid-cap stocks with possible market-moving data due at the meeting. And, we’ve included our thoughts on some potential trades.
Karyopharm (KPTI)
Karyopharm will offer the first glimpse at what its exportin-1 antagonist and inhibitor of nuclear export selinexor can do in solid tumor indications at ASCO this year.
Karyopharm’s selinexor, called a SINE (Selective Inhibitor of Nuclear Export), is a novel approach to treating cancers and is already in three registration-directed (phase 2/3) clinical trials in hematologic (blood) cancers: diffuse large B-cell lymphoma (DLBCL), Richter’s transformation, and acute myeloid leukemia (AML). Top-line data from these three studies are expected in the second half of 2016. Karyopharm also plans to initiate a single-arm trial in multiple myeloma in the near-term. If data from an initial 80 patients are promising, the study will be expanded to potentially support accelerated approval in this indication.
In the meantime, investors are eager to see what selinexor can do in solid tumor indications. The company has begun four Phase 2 solid tumor studies in gynecologic malignancies (the SIGN Study); glioblastoma multiforme (the KING Study); metastatic prostate cancer (the SHIP Study); and squamous head and neck, lung & esophageal cancers (the STARRS Study). A study in liposarcoma is ongoing as well. Karyopharm will present interim data from SIGN and KING at “mid-year”, along with further data from the liposarcoma study. ASCO is a likely venue.
Additionally, fourteen abstracts on selinexor have been selected for presentation at the 2015 Annual Meeting of the American Association for Cancer Research (AACR), which takes place from April 18-22. 
Already a Premium user? Sign In
